Skip to main content
Premium Trial:

Request an Annual Quote

Arthur Holden, Shaf Yousaf, Barbara Preisel-Simmons

Premium
Arthur Holden plans to leave his post as vice president of corporate and market development at Illumina in mid-October, the company said this week in a filing with the US Securities and Exchange Commission.
 
Holden is director of the Serious Adverse Events Consortium, a pharma-backed initiative announced last week that aims to find genetic causes for serious adverse events that hamper drug development. He was formerly chairman and CEO of First Genetic Trust, and also held leadership positions at the Pharmaceutical Biomedical Research Consortium, the DMD Translational Research Consortium, and the SNP Consortium.
 

 
Shaf Yousaf has joined Applied Biosystems as president of the Molecular and Cell Biology Systems division. He joined ABI from Sigma-Aldrich, where he was president of the research biotech business unit.
 
In July, Applied Biosystems split its Molecular and Cell Division into two groups: MCB Systems and MCB Consumables.
 
At the time, Mark Stevenson, president of the Molecular and Cell Division, was promoted to executive vice president of the company. Peter Dansky heads the MCB Consumables group.
 

 
Exagen Diagnostics said this week it has hired Barbara Preisel-Simmons to be senior director of clinical affairs, a new position focused on overseeing clinical trials. Preisel-Simmons previously worked for Siemens Medical Solutions Diagnostics, Bayer HealthCare, Chiron Diagnostics, Abbott Laboratories, and Baxter Healthcare.

Filed under

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.